pT-stage was <pT2 in 80, pT2 in 241, pT3 in 410 and pT4 in 173 patients, respectively. Cancer positive nodes were found in 342 (38%) patients. The FGFR3 mutation was found in 102 RCs (11%), aberrant p53 in 639 (71%) RCs and aberrant Ki-67 in 502 (56%) RCs. The FGFR3 mutation was associated with lower pT-stage (P<0.001), G2 (P<0.001), pN0 (P=0.002) and prolonged DSS (P=0.001). Aberrant Ki-67 and p53 were associated with higher pT-stage and G3 tumors but not with pN+ or worse DSS. Significant predictors in multivariable analysis were pT-stage (HR 2.7, 95% CI: 1.6-4.5; P<0.001), LVI (HR 1.5, 95% CI: 1.2-1.8; P=0.001), pN-stage (HR 1.9, 95% CI: 1.5-2.3; P<0.001) and FGFR3 mutation status (HR 1.6, 95% CI: 1.1-2.3; P=0.018).
In summary, the FGFR3 mutation selectively identified patients with favorable BC at RC while p53 and Ki-67 expression were only associated with adverse tumor-characteristics. Tumor stage, LVI and nodal status remained strong predictors of DSS in this multi-center, multi-lab study enhancing the generalizability of their findings.
Presented by: Laura Mertens, University Health Network, Princess Margaret Hospital & Mount Sinai
Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 16th Annual Meeting of the International Bladder Cancer Network (IBCN) October 11-13, 2018 - the Inntel Hotels Rotterdam Centre, Rotterdam, The Netherlands